RecruitingNot ApplicableNCT06675240
Meditative Neurofeedback for Depression
Sponsor
University of California, San Diego
Enrollment
27 participants
Start Date
Nov 15, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this study is to test a meditative neurofeedback intervention for depressed mood.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is testing a new approach called meditative neurofeedback as a treatment for depression. Neurofeedback trains people to regulate their own brain activity in real time using visual or audio signals, and this study combines that with meditative practices to target mood regulation.
**You may be eligible if...**
- You are experiencing moderate depression based on a standard questionnaire (PHQ-9)
**You may NOT be eligible if...**
- You have an active substance abuse or dependence problem
- You have a psychotic disorder (such as schizophrenia)
- You have bipolar disorder
- You are currently experiencing acute suicidal behavior
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BEHAVIORALMediNF
Over 10-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided to enhance performance.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06675240
Related Trials
An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.
NCT07373470
Characterizing Synaptic Density in Treatment Resistant Depression
NCT035377941 location
Lumateperone for Late-Life Depression
NCT07623135
Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study
NCT07203144
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT0679339768 locations